CDMO marketing strategy: getting shortlisted before the RFP

How sponsors choose a CDMO

A sponsor looking for a development or manufacturing partner usually starts with a long list from its own experience, colleagues, databases and search, then narrows it on fit: modality and scale, the analytical and formulation capability the molecule needs, quality systems and inspection history, capacity and timelines, location and supply security, and the people. Only the short list receives the RFP. A CDMO that is not visible and credible during that narrowing does not get the chance to answer, however strong its proposal would have been.

Rule 1: Registration is not approval

Under 21 CFR 207.77(a), registration of an establishment or listing of a drug does not denote approval of the establishment, the drug or other drugs of the establishment, and any representation that creates an impression of official approval because of registration or listing is misleading and constitutes misbranding. "FDA-approved facility" is therefore wrong. Say "FDA-registered" if it is registered, and give inspection history only as the facts stand, with dates, approved by your quality team.

Rule 2: DMFs, CEPs and GMP need the documents

The FDA's Drug Master Files page says DMFs are submissions that provide confidential detailed information about facilities, processes or articles, that they are not required by statute or regulation, and that they are neither approved nor disapproved; FDA reviews their technical contents in connection with the applications that reference them. "DMF on file" with the type and number, where you choose to publish them, is accurate; "DMF-approved" is not.

In Europe, the EDQM issues certificates of suitability to the monographs of the European Pharmacopoeia (CEPs) and keeps a certification database; claim a CEP only for the substances it covers and link the database entry where you can. Current good manufacturing practice for drugs in the USA is set out in 21 CFR Part 210 and Part 211; a GMP claim names the system and the inspection or certificate behind it.

Rule 3: No therapeutic claims for an API, and care with controlled substances

An active pharmaceutical ingredient maker sells a material to a sponsor; claims about what a medicine treats belong to the finished product's labeling and its approval, not to the API supplier's website. Describe the substance, its grades, specifications, scale and quality, and stop there. Some precursors are regulated: the DEA's List I chemicals, such as ephedrine, are covered by registration and reporting rules, so they are never promoted loosely and inquiries go to the team that screens them. In Canada, Health Canada's establishment licence rules say all Canadian drug establishments must hold, since 1 January 1998, an establishment license to fabricate, package, label, distribute, import, wholesale or test a drug; state a license only if you hold it.

Part 1: Capability pages stated exactly

Each capability or site gets a page with six parts:

• Modalities and dosage forms: small molecule, peptide, biologic, oral solid, sterile injectable and so on, as you run them.
• Scale and equipment: reactor volumes, suites, lines and batch sizes in the terms you choose to share.
• Analytical and development capability: methods, instruments, stability programs and the problems your scientists solve.
• Quality and regulatory history: quality systems, registrations, DMFs and CEPs held, inspection history as facts with dates.
• Sites and supply: where each step happens, capacity windows, and business continuity.
• People: the named scientists and project leads a sponsor will work with.

Part 2: Technical content written by your scientists

Development teams read content that helps them decide: a scale-up case described without the sponsor's name, a note on a difficult crystallization or a solubility problem, a guide to tech transfer, a regulatory explainer. CMI's 2027 B2B content research found 52% of B2B marketers say their organization has no policy on disclosing AI use; in this industry, a named scientist and a reviewer on every technical piece matters more than speed. Google's helpful content guidance asks whether a page shows first-hand expertise. Our spoke on life science content marketing covers the plan.

Part 3: Be found for the problems development teams search

Sponsors search for a capability plus a constraint: "HPAPI containment contract manufacturer", "spray drying CDMO", "peptide synthesis scale-up". Those searches should land on your capability pages. Pew Research Center found in March 2025 that Google users who saw an AI summary clicked a traditional result 8% of the time, against 15% without one, as its report describes; specific, first-hand pages are the kind that summaries cite. Our spoke on life science SEO covers the work.

Part 4: LinkedIn for named roles at sponsors

The audience is small and named: heads of CMC, external manufacturing, sourcing and development at a few hundred sponsors in your modality. LinkedIn's ad targeting reaches members by job title, company, industry and seniority. Use it to put a technical piece in front of the roles that build long lists, to support a new capability launch, and to warm accounts before a sales visit. Our LinkedIn advertising page covers the setup.

Part 5: A relationship cadence between projects

Sponsors return to CDMOs that delivered, and project leads move between companies. Keep a named list of sponsor contacts and alumni, and keep useful contact through the year: a capability update, a technical note, an invitation to an audit or a site visit. Email to these contacts is commercial email: in the USA the FTC's CAN-SPAM guide requires accurate headers, a postal address and an opt-out honored within 10 business days, with penalties up to $53,088 per email, and in Canada CASL requires consent first.

Part 6: The website that holds it together

The website is where a sourcing team checks everything above in one sitting. It needs capability and site pages, a quality and regulatory page with exact wording, scientist profiles, technical content, and a confidential inquiry path that asks the right questions about the molecule and the timeline. Our spoke on life science website design covers the build.

Part 7: The RFP, answered from proof

When the RFP arrives, the work in parts 1 to 6 pays back: the capability language, the quality wording, the case descriptions and the people are already written and approved. A strong response answers the sponsor's questions in their order, proposes a realistic timeline with its assumptions, names the team, and makes every regulatory statement exactly as true as your quality team will sign. Our spoke on the CDMO RFP covers it step by step.

How to measure it

Each quarter, by modality: appearances on sponsor long lists and short lists you can trace, RFPs received, proposals submitted, proposals won, projects started, repeat sponsors, and the time from first contact to project start. Visits, downloads and followers are context. Debrief every lost proposal; the reasons tell you which capability pages to improve.

If you want it run with you

PromotEdge International is an international strategy, technology, marketing and design company, and our delivery team is in India. Life science clients we have worked for include Kopran and Novozymes. That work was for their business in India and was delivered by our team there. Our life science marketing service page describes the work; we never use the words "FDA-approved facility", and your quality team approves every regulatory statement. This guide is general information, not legal or regulatory advice; your counsel and regulatory team have the last word.

Facts we rely on: see our company facts for what we state about ourselves and where each fact comes from.